Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals
nosair, A., ismail, W., Hamed, E., Salem, G. (2020). Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals. EKB Journal Management System, 26(5), 877-882. doi: 10.21608/zumj.2019.13982.1278
asmaa haroun nosair; waleed ismail; Emad F Hamed; Ghada Mohammed Salem. "Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals". EKB Journal Management System, 26, 5, 2020, 877-882. doi: 10.21608/zumj.2019.13982.1278
nosair, A., ismail, W., Hamed, E., Salem, G. (2020). 'Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals', EKB Journal Management System, 26(5), pp. 877-882. doi: 10.21608/zumj.2019.13982.1278
nosair, A., ismail, W., Hamed, E., Salem, G. Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals. EKB Journal Management System, 2020; 26(5): 877-882. doi: 10.21608/zumj.2019.13982.1278

Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals

Zagazig University Medical Journal
Article 251, Volume 26, Issue 5, September 2020, Page 877-882  XML PDF (588.38 K)
Document Type: Original Article
DOI: 10.21608/zumj.2019.13982.1278
View on SCiNiTO View on SCiNiTO
Authors
asmaa haroun nosair email 1; waleed ismail2; Emad F Hamed3; Ghada Mohammed Salem4
1post graduate in Internal Medicine department, Zagazig University.
2internal medicine department,faculty of medicine, zagazig university
3Internal Medicine department, Faculty of medicine,Zagazig university, Egypt
4Community and public health department faculty of medicine. Zagazig university
Abstract
Background: According to World Health Organization (WHO) estimates, the prevalence of HCV in Egypt is 4.5% to 6.7%, which is the uppermost prevalence of HCV in the world causing a substantial burden of mortality and morbidity. Health related quality of life [HRQoL] has been assessed in diabetes, arthritis and a wide variety of cancers, Until now, there is no sufficient report about HRQoL related to direct acting antiviral agents (DAAs )on Egyptian patients with chronic HCV. This prospective cohort study aimed to assess the health related quality of life in Egyptian patients with chronic HCV treated with daclatasvir (DAC) and sofosbuvir(SOF) ± ribavirin (RBV). Methods: One hundred HCV patients were classified according to the supreme council and national committee for control of HCV (NCCVH) into two groups: Group 1 (easy to treat) included 35 patients treated with SOF+DAC for 12 weeks, and group 2 (difficult to treat) included 65 patients treated with SOF+DAC+RBV for 12 weeks. The short form 36 scale (SF-36) was used to assess the health related quality of life in two groups. Results: Sustained virological response (SVR12) in patient received DAC/SOF was 83.3 % and in patient received DAC/SOF/RBV was 100% (Total 93%). The patients reported significant improvement in all HRQoL domains after therapy, group1reported higher improvement. Conclusion: Sofosbuvir and Daclatasvir with or without ribavirin are effective in treatment of chronic HCV infections with low adverse actions and better improvement in HRQoL. Sofosbuvir and Daclatasvir have better improvement in HRQoL than Sofosbuvir and Daclatasvir plus ribavirin.
Keywords
HCV; Daclatasvir; Sofosbuvir; Health related quality of life; SF-36 scale
Statistics
Article View: 341
PDF Download: 268